Bunkerhill MAC vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 70/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Bunkerhill MAC

by Bunkerhill Health

EchoNext

by Pathway Labs

AI Verdict

Both Bunkerhill MAC and EchoNext are FDA-cleared AI tools in cardiology, offering clinical decision support. Bunkerhill MAC focuses on detecting and quantifying mitral annular calcification from CT scans, aiding in early cardiovascular risk identification. EchoNext, on the other hand, analyzes ECGs to detect hidden structural heart disease, including heart failure and valve disease, providing a different diagnostic approach.

Choose Bunkerhill MAC if…

Choose Bunkerhill MAC if your institution frequently performs routine CT scans for various indications and you want to opportunistically screen for mitral annular calcification (MAC) to identify patients at increased cardiovascular risk. This tool excels at integrating into existing radiology workflows to quantify MAC, which might otherwise be missed, and can help automate follow-up and care coordination within the Carebricks platform.

View Bunkerhill MAC →

Choose EchoNext if…

Choose EchoNext if your primary goal is to leverage standard 12-lead ECGs for early, non-invasive detection of hidden structural heart diseases, including heart failure, valve disease, and pulmonary hypertension. This tool is ideal for broad screening in various clinical settings, from major hospitals to community practices, to identify high-risk patients who warrant further cardiac evaluation like an echocardiogram.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Bunkerhill MAC	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Cloud-based, integrated with existing EHRs and clinical systems via Carebricks platform.	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Yes AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Bunkerhill MAC

Bunkerhill MAC is integrated with the Carebricks platform, which is designed to seamlessly integrate with existing EHRs and clinical systems and automate workflows. This suggests a strong focus on minimizing disruption to current clinical practices. EchoNext is available through the OpenEvidence platform, which serves a large number of physicians, but the description doesn't explicitly detail the level of workflow integration or ease of use within that platform.

Clinical Value

EchoNext

EchoNext has demonstrated high accuracy in detecting a range of structural heart problems from ECGs, even outperforming cardiologists in some studies. It aims to bridge a critical gap by identifying hidden structural heart disease earlier, potentially leading to life-saving interventions. While Bunkerhill MAC is also FDA-cleared and addresses an important, often overlooked finding, the breadth of conditions detected by EchoNext and its comparative performance against human experts suggest a higher immediate clinical impact.

Pricing & Value

EchoNext

EchoNext provides transparent tiered pricing starting at $600/month, including details on implementation fees and discounts. Bunkerhill MAC states 'contact for pricing,' which offers no transparency. Therefore, EchoNext offers clearer value proposition due to its transparent pricing structure.

Enterprise Readiness

Bunkerhill MAC

Bunkerhill MAC is part of the Carebricks platform, which is described as a generative AI platform for clinical reasoning and action, already being used by major health systems like Cleveland Clinic and Mayo Clinic. This indicates a robust enterprise-level deployment and integration capability across various clinical and administrative workflows. EchoNext's deployment through OpenEvidence also suggests broad access, but Carebricks' broader scope and existing adoption by large health systems point to a more comprehensive enterprise readiness.

Innovation

EchoNext

EchoNext is highlighted as the world's first FDA-approved AI detection tool that analyzes standard ECGs to detect hidden structural heart disease, a capability traditionally not possible with ECGs alone. This represents a significant advancement in leveraging a common, inexpensive test for early detection of complex cardiac conditions. While Bunkerhill MAC is also a first-of-its-kind for MAC detection, EchoNext's ability to transform the utility of a widely available diagnostic tool for multiple conditions demonstrates a higher degree of innovation.

Support & Docs

Tie

Neither the provided structured facts nor the web search results offer specific details regarding the level of customer support, training, or documentation available for either Bunkerhill MAC or EchoNext. Therefore, it is not possible to definitively pick a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Bunkerhill MAC	EchoNext
Name	Bunkerhill MAC	EchoNext
Company	Bunkerhill Health	Pathway Labs
Tagline	Generative AI for clinical reasoning and action.	How's your heart?
Description	Bunkerhill MAC is an FDA-cleared AI algorithm by Bunkerhill Health that detects and quantifies mitral annular calcification (MAC) on routine CT scans, aiding early cardiovascular risk identification and care coordination within the Carebricks platform.	EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Features	AI-powered detection and quantification of Mitral Annular Calcification (MAC); Analyzes routine, non-gated chest CT scans; Identifies patients at increased cardiovascular risk; Integrates with the Carebricks generative AI platform for clinical reasoning and action; Supports automated workflows for follow-up and care coordination; Developed and validated through a multi-institutional research consortium; Seamless integration with existing EHRs and clinical systems	AI-powered ECG analysis; Detection of hidden structural heart disease; Identifies heart failure risk; Screens for valve disease; Detects pulmonary hypertension indicators; Utilizes standard 12-lead ECGs; FDA-cleared technology; Non-invasive diagnostic support

Videos

Demos, reviews, and walkthroughs featuring Bunkerhill MAC and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

Bunkerhill MAC integrates with existing EHRs and clinical systems via the Carebricks platform, which is designed to customize workflows and automate next steps. EchoNext is available through the OpenEvidence clinical decision support platform, which aims to embed its screening output directly into tools physicians already use, avoiding separate workflows.

What is the accuracy and sensitivity of each tool in detecting cardiovascular conditions?

Bunkerhill MAC detects and quantifies mitral annular calcification (MAC) on routine CT scans, a condition linked to increased cardiovascular risk. EchoNext, trained on over 1.2 million ECG-echocardiogram pairs, achieved an AUROC of 85.2% in internal tests and 78-80% in external validation for detecting structural heart disease, outperforming cardiologists in studies.

Given their specialized focus, how do these tools fit within different cardiology subspecialties or broader clinical contexts?

Bunkerhill MAC is specifically focused on identifying and quantifying mitral annular calcification from routine CT scans, which is relevant for cardiologists and radiologists in assessing cardiovascular risk and guiding structural heart procedures. EchoNext, by analyzing standard ECGs to detect hidden structural heart disease like heart failure, valve disease, and pulmonary hypertension, serves as a broad screening tool for cardiologists, family medicine, hospital medicine, and internal medicine, aiming for earlier detection before symptoms appear.

What is the typical learning curve for physicians and clinical staff to effectively use these AI tools?

Bunkerhill MAC is designed to be seamlessly embedded into existing workflows, suggesting a focus on ease of use and minimal disruption. EchoNext's integration with the OpenEvidence platform aims to put the screening output directly into tools physicians already use, which could reduce the learning curve by leveraging familiar interfaces.

Can these tools provide audit trails or features for tracking and reviewing AI-driven recommendations and actions?

Bunkerhill MAC operates within the Carebricks platform, which enables health systems to customize workflows that automate appropriate next steps and apply AI-powered reasoning across patient data, implying a system capable of tracking actions. While not explicitly detailed for EchoNext, its deployment through a clinical decision support platform suggests a framework for integrating and potentially auditing AI-assisted analyses.

What kind of customer support and resources are available to ensure successful implementation and ongoing utilization?

Bunkerhill Health's Carebricks platform is designed to help health systems improve outcomes and increase efficiency without adding to clinician workload, suggesting comprehensive support for implementation and ongoing use. Pathway Labs aims to integrate EchoNext into real workflows across health systems at a national scale, indicating a commitment to supporting widespread adoption.

Are there customer references or case studies available that demonstrate the real-world impact and time-to-value of these tools in clinical settings?

Bunkerhill MAC is part of the Carebricks platform, which is already being used at major health systems like Cleveland Clinic and Mayo Clinic, and has been recognized for its AI implementation. EchoNext has been evaluated in studies across over 20 hospitals and 500,000 patients, with a published case in Nature Medicine where it detected undiagnosed heart failure leading to a heart transplant.